ArticleEnvironment & health (Washington, D.C.)2025
Integrating Disease Data and Toxicology Studies to Uncover the Mechanisms of Indium Tin Oxide (ITO) Nanoparticle-Induced Pulmonary Fibrosis and Develop an Adverse Outcome Pathway (AOP) Framework.
Article in Environment & health (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Role of Cellular-Ferroptosis-Mediated HMGB1 Nuclear Translocation in Indium-Tin-Oxide-Nanoparticle-Induced Inflammatory Lung Injury.Environment & health (Washington, D.C.) · 2026Article
- Clinical value of IL-17-targeted intervention in tissue injury repair: from bidirectional mechanisms to therapeutic strategies.Frontiers in immunology · 2026Review
- Key Molecular Cascade in Indium Tin Oxide Nanoparticle-Induced Pulmonary Fibrosis.Environment & health (Washington, D.C.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure to indium tin oxide (ITO) nanoparticles (NPs) is strongly correlated with the development of indium lung disease. Preliminary studies have explored mechanisms of ITO NP-induced pulmonary toxicity, but a gap remains in effective methods for risk assessments. To address this issue, we integrated data from population disease databases with traditional toxicology and RNA sequencing to conduct mechanistic studies and establish an adverse outcome pathway (AOP) for ITO NP-induced lung injury. Our findings demonstrate that exposure to ITO NPs induces early pulmonary fibrosis, characterized by a persistent inflammatory response in mice. Mechanistic analysis reveals that lung injury is driven by the activation of the NF-κB signaling pathway mediated by IL-17A in macrophages. In the AOP framework for ITO-induced pulmonary fibrosis, IL-17A serves as a molecular initiating event, initiating the activation of the NF-κB signaling pathway in macrophages. This activation results in the production of inflammatory cytokines (IL-1β and TNF-α) and fibrogenic factors (TGF-β1), ultimately triggering a cellular-level inflammatory response. The sustained inflammation further promotes microvascular leakage, which is a key contributor to the progression of pulmonary fibrosis. The qualitative and quantitative evaluations of supportive inconsistent evidence for MIE and KEs show that the confidence of this AOP is moderate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.